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Can the FDA Improve Oversight of Foreign
Clinical Trials?: Closing the Information Gap
and Moving Towards a Globalized Regulatory
Scheme
Andrd Ourso*
In June 2010, national news sources reported on a recently released
government report concerning the Food and Drug Administration's (FDA)
ability to monitor foreign clinical trials used to support marketing
applications for pharmaceutical products sold in the U.S.' The report was
prepared by the Office of Inspector General of the Department of Health
and Human Services (OIG), and found that for the fiscal year 2008, 80% of
approved marketing applications for drugs and biologics contained data
from foreign clinical trials.2 In 2008, 78% of all subjects who participated
in clinical trials were enrolled at foreign sites, and over 54% of all clinical
trial sites were located outside the United States. The report also indicated
that the FDA faced challenges to conducting foreign inspections and data
limitations inhibited the agency's ability to monitor foreign clinical trials.4
The report found that the FDA inspected just 0.7% of foreign clinical trial
*Mr. Ourso is recent graduate of the University of Florida Levin College of Law. He also
holds a Master of Public Health with a concentration in Epidemiology from the University of
South Florida. During law school Andrd worked as a research assistant at the University of
Florida College of Medicine, Institute for Child Health Policy. He currently works as a staff
attorney at the Florida Department of Health, Prosecution Services Unit, Medical Division.
The author would like to thank Prof. Lars Noah at the University of Florida Levin College of
Law for his correspondence and comments during the drafting of this article.
1. See generally Gardiner Harris, Concern Over Foreign Trialsfor Drugs Sold in U.S.,
N. Y. TIMES (Jun. 21, 2010), http://www.nytimes.com/2010/06/22/health/research
/22trial.html?_r-1&hpw; Laura Strickler, Report Raises Concern Over Foreign Drug Trials,
CBS NEWS (Jun. 22, 2010), http://www.cbsnews.com/8301-31727_162-2000851010391695.html.
2. OFFICE OF INSPECTOR GEN., DEP'T OF HEALTH & HUM. SERVS., OEI-01-08-00510,
CHALLENGES TO FDA's ABILITY TO MONITOR AND INSPECT FOREIGN CLINICAL TRIALS 10
(2010) [hereinafter OIG, CHALLENGES], http://oig.hhs.gov/oei/reports/oei-01-08-00510.pdf

(reporting: (1) to determine the extent to which sponsors submitted data from foreign clinical
trials to support drug and biologic marketing applications by the FDA in fiscal year 2008 and
(2) to determine the extent to which the FDA monitors and inspects foreign clinical trials
that support marketing applications).
3. Id.
4. Id. at 17.

493

Published by LAW eCommons, 2012

1

Annals of Health Law, Vol. 21 [2012], Iss. 2, Art. 8

494

Annals of Health Law

[Vol. 21

sites.' This report is not the first time that the OIG has addressed concerns
about FDA's oversight of clinical trials and foreign clinical trials.6
Pharmaceutical companies' utilization of data from foreign clinical trials
to support marketing applications for drugs sold in the U.S. is not a recent
result of the phenomenon of globalization. The emergence of foreign
clinical trials began almost two decades ago.7 From 1990 to 1999, the
number of foreign clinical investigators conducting drug research under
Investigational New Drug Applications (IND) increased sixteen-fold.8
From 1998 to 2008, the percentage of foreign clinical investigators
conducting clinical trials under INDs has more than doubled.9 Presently,
sponsors' utilization of foreign clinical trial data is ubiquitous and
commonly considered an indispensable aspect of gaining drug approval.o
A recent study, searching the ClinicalTrial.gov website, found that the
twenty largest U.S. based pharmaceutical companies were conducting onethird of their clinical trials exclusively at foreign sites."
There are several reasons for the movement of clinical trials overseas,
Pharmaceutical companies can
especially to developing countries.
substantially save costs conducting trials in developing countries. 12 A firstrate academic medical center in India may charge one-tenth the cost a
second-tier medical center in the U.S. would charge.13 A decrease in
volunteers for clinical trials in the U. S. is also contributing to the shift of
trials overseas. 14 Volunteers in the U.S. are scarce because Americans are
5.
6.

Id. at 15.
See OFFICE OF INSPECTOR

7.

OIG, THE GLOBALIZATION OF CLINICAL TRIALS, supra note 6, at 6.

GEN., DEP'T OF HEALTH & HUM. SERVS., OEI-01-00-00190,
THE GLOBALIZATION OF CLINICAL TRIALS: A GROWING CHALLENGE IN PROTECTING HUMAN
SUBJECTS, (2001) [hereinafter OIG, THE GLOBALIZATION OF CLINICAL TRIALS]; OFFICE OF
INSPECTOR GEN., DEP'T OF HEALTH & HuM. SERVS., OEI-0 1-06-00160, THE FOOD AND DRUG
ADMINISTRATION'S OVERSIGHT OF CLINICAL TRIALS (2007).

8. Id.
9. OIG, CHALLENGES, supra note 2, at 13.
10. 21 C.F.R. § 312.3(b) (2011) ('Sponsor' means a person or entity who takes
responsibility for and initiates a clinical investigation. The sponsor may be an individual or
pharmaceutical company, governmental agency, academic institution, private organization,
or other organization).
11. Seth W. Glickman et al., Ethical and Scientific Implications of the Globalization of
ClinicalResearch, 360 NEw ENG. J.MED. 816, 816 (Feb. 19, 2009) (registering federally and
privately supported clinical trials conducted in the United States and around the world,
ClinicalTrials.gov provides information about a trial's purpose, who may participate,
locations, and contact information. As a result of the FDA Modernization Act (FDAMA),
Pub. L. No. 105-115, 111 Stat. 2296 (1997), the National Institute of Health (NIH), through
its National Library of Medicine (NLM), developed the site in collaboration with the FDA,
About

ClinicalTrials.gov,

NAT'L INST.

OF

HEALTH

(last

updated

Apr. 2,

2008),

http://clinicaltrials.gov/ct2/info/about).
12. See id
13. Id.
14.

SONIA SHAH, THE BODY HUNTERS: TESTING NEW DRUGS ON THE WORLD'S POOREST
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more reluctant to join risky experiments. 5 Developing countries may also
have a higher prevalence of certain diseases, making clinical trials easier to
organize. 16 In addition, patients in developing countries with little exposure
to medications make better subjects for clinical testing.' 7 For example,
India is an appealing country for sponsors to conduct clinical trials because
it has a genetically diverse population of over one billion people who have a
myriad of diseases yet have not been exposed to many medications.
Furthermore, conducting clinical trials globally shortens the timeline for
clinical testing.' 9 A sponsor may have a larger pool of volunteers to enroll
participants in trials in foreign and developing countries than in the U.S. 20
A larger pool of potential clinical trial participants, combined with the
lower cost of research, accelerates recruitment.2 1 Cutting down the time
and expense until a drug is approved and brought to market saves sponsors
a significant amount of the total cost of drug development.22
Another reason sponsors conduct clinical trials in foreign countries is
because it may be a prerequisite to marketing approval in those countries.23
Moreover, stronger intellectual property protections and the widespread
adoption of certain international standards make drug approval more
conducive and cost efficient in foreign countries, especially in those of the
developing world.2 4 Not surprisingly, many foreign clinical trials are
conducted in developing nations.25
Despite advantages in conducting clinical trials in developing countries,
there is some skepticism regarding foreign clinical trials, including
concerns about questionable data and verifying clinical results.2 6 Foreign
clinical trials also raise concerns about the ethical treatment of human
subjects enrolled in these trials, particularly in countries where enforcement
PATIENTS 5 (2006).

15. Mary Flaherty, Deborah Nelson & Joe Stephens, Testing Tidal Wave Hits Overseas,
WASH. PosT, Al (Dec. 18, 2000), http://www.washingtonpost.com/wp-dyn/Content
/article/2008/10/0l/AR2008100101117.html (addressing the issue of emerging international
clinical drug trials and its ethical and safety implications in part two of a six part series
entitled, The Body Hunters).
16. Id.
17. Id.
18. Samiran Nundy & Chandra Gulhati, A New Colonialsim? - Conducting Trials in
India, 352 NEW ENG. J. MED. 1633, 1634 (Apr. 21, 2005).

19. Glickman et al., supra note 11, at 816.
20. Id. at 817.
21. Id.
22. Id
23. Id.
24. Id.
25. Donald L. Bartlett & James B. Steele, Deadly Medicine, VANITY FAIR (Jan. 2011),
http://www.vanityfair.com/politics/features/20 11/0 1/deadly-medicine-20 1101.
26. Strickler, supranote 1; see also Harris,supranote 1.
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of regulation and human subject protection may be inadequate. 27 There
may be an even greater risk of unethical treatment in developing countries
where potential subjects are unaware of the notion of informed consent.28
In the past, lack of trust has been focused on the government support and
involvement in unscrupulous clinical studies, such as the infamous
Tuskegee syphilis studies in the U.S., and the recently uncovered
experiments on sexually transmitted diseases in Guatemala. 2 9 Today, there
may be greater concern with multinational pharmaceutical companies

27. See Madhur Singh, Should Clinical Trials Be Outsourced?, TIME.COM (Aug. 7,
2008), http://www.time.com/time/health/article/0,8599,1830334,00.html.
28. Finnuala Kelleher, The Pharmaceutical Industry's Responsibility for Protecting
Human Subjects of Clinical Trials in Developing Nations, 38 COLUM. J.L. & SOC. PROBS. 67,
69 (2004-2005); see also Int'l Conference on Harmonisation of technical requirements for
registration of pharmaceuticals for human use, Good Clinical Practice, Informed Consent of
Trial Subjects §4.8.10, ICHGCP.NET, http://ichgcp.net/4-investigator (establishing best
practice on informed consent discussions and written forms to include information that; (a)
the trial involves research, (b) The purpose of the trial, (c) The trial treatment(s) and the
probability for random assignment to each treatment, (d) The trial procedures to be followed,
including all invasive procedures, (e) The subject's responsibilities, (f) Those aspects of the
trial that are experimental, (g) The reasonably foreseeable risks or inconveniences to the
subject and, when applicable, to an embryo, fetus, or nursing infant, (h) The reasonably
expected benefits. When there is no intended clinical benefit to the subject, the subject
should be made aware of this, (i) The alternative procedure(s) or course(s) of treatment that
may be available to the subject, and their important potential benefits and risks, (j) The
compensation and/or treatment available to the subject in the event of trial-related injury, (k)
The anticipated prorated payment, if any, to the subject for participating in the trial, (1) The
anticipated expenses, if any, to the subject for participating in the trial, (in) That the subject's
participation in the trial is voluntary and that the subject may refuse to participate or
withdraw from the trial, at any time, without penalty or loss of benefits to which the subject
is otherwise entitled, (n) That the monitor(s), the auditor(s), the IRB/IEC, and the regulatory
authority(ies) will be granted direct access to the subject's original medical records for
verification of clinical trial procedures and/or data, without violating the confidentiality of
the subject, to the extent permitted by the applicable laws and regulations and that, by
signing a written informed consent form, the subject or the subject's legally acceptable
representative is authorizing such access, (o) That records identifying the subject will be kept
confidential and, to the extent permitted by the applicable laws and/or regulations, will not
be made publicly available. If the results of the trial are published, the subject's identity will
remain confidential, (p) That the subject or the subject's legally acceptable representative
will be informed in a timely manner if information becomes available that may be relevant to
the subject's willingness to continue participation in the trial, (q) The person(s) to contact for
further information regarding the trial and the rights of trial subjects, and whom to contact in
the event of trial-related injury, (r) The foreseeable circumstances and/or reasons under
which the subject's participation in the trial may be terminated, (s) The expected duration of
the subject's participation in the trial, (t) The approximate number of subjects involved in the
trial).
29. See generally Robert Bazell, U.S. apologizesfor Guatemala STD experiments, NBC
NEWS (Oct. 1, 2010, 7:05 PM), http://www.msnbc.msn.com/id/39456324/ (citing two
egregious instances involved the nonconsensual infection of syphilis or gonorrhea into
patients. The studies were sponsored by the U.S. Public Health Service, and in the case of
Guatemala, the Guatemalan government).
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sponsoring unethical clinical trials.3 0 There is also unease with independent
contractors hired by sponsors to recruit and enroll potential patients
overseas. 3 1 These companies employ technicians who are paid to gather a
certain number of human subjects and even conduct the clinical trials
themselves. 32 These contract research organizations (CROs) generate
annual revenue of $20 billion.33
One notorious and egregious example of such trials was Pfizer's study of
Trovan in Nigeria. In 1996, in the midst of a bacterial meningitis outbreak
in Nigeria, Pfizer set up a medical camp in Kano where child victims of the
outbreak could receive treatment and medication while allowing Pfizer to
conduct clinical trials on its promising new antibiotic, Trovan.
Unbeknownst to the patients and their families, the non-profit aid group
Medecins Sans Frontieres (Doctors Without Borders) set up a medical camp
in the very same area prior to the arrival of Pfizer's team. Doctors Without
Borders had been administering proven-effective antibiotics to patients free
of charge.35 Conflicts between the two groups arose, with Pfizer's team
disrupting the existing triage system and co-opting the scarce resources.
After quickly conducting its trials, Pfizer left Kano without offering any
long-term follow up care to its human subjects.
Pfizer reportedly enrolled many of the patients in the drug trial without
obtaining the informed consent of either the subjects or their parents. The
FDA found inconsistencies in the data Pfizer submitted from the Kano trial,
and, in1999, post-marketing reports revealed a strong association between
Trovan and an increased risk of acute liver failure.39 In June 1999, the FDA
issued a public health advisory concerning reports of liver toxicity and
failure associated with the use of trovafloxacin. 40 The FDA advised
30. See Strickler, supra note 1.
31. See Bartlett & Steele, supra note 25.
32. Id.
33. Id.
34. Joe Stephens, Where Profits and Lives Hang in the Balance, WASH. POST, Al (Dec.
17, 2000), http://www.
washingtonpost.com/wp-dyn/content/story/2008/10/01/ST2008100101390.html (addressing
ethical and safety implications of emerging international clinical drug trials. Part one of a
six part series entitled, The Body Hunters, describes events surrounding Pfizer's testing of
the antibiotic, trovafloxacin (sold by Pfizer as Trovan) on children in Nigeria suffering from
meningitis).
35. Id.
36. Id.
37. Id
38. Id.
39. Melody Petersen, Unforeseen Side Effects Ruined One Blockbuster, N.Y. TIMES
(Aug. 27, 2000), http://www.nytimes.com/2000/08/27/business/unforeseen-side-effectsruined-one-blockbuster.htnl.
40. Murray M. Lumpkin, M.D., Food and Drug Administration 09 June 1999 Trovan

Published by LAW eCommons, 2012

5

Annals of Health Law, Vol. 21 [2012], Iss. 2, Art. 8

Annals of Health Law

498

[Vol. 21

physicians to limit use of trovafloxacin to certain seriously-ill *patients. 41
The Trovan studies raised serious concerns about the unethical treatment of
human subjects, including lack of informed consent and lack of proper
follow-up care.42 Government corruption and lack of oversight were also
problems in Nigeria that presumably contributed to the controversy
surrounding the studies.
While Pfizer's Trovan trial is a particularly shocking example, foreign
clinical trials are commonly associated with concern over the ability of
foreign regulatory bodies and institutional review boards to adequately
monitor clinical trials to protect the rights, safety, and welfare of human
subjects and ensure data integrity.4 4 Sponsors' utilization of foreign clinical
trials in which unethical treatment of human subjects occurs, or where
tainted data is used to support drug marketing applications, may pose a
significant danger to patients' health and the integrity of scientific
research.45
. FDA REGULATION OF FOREIGN CLINICAL TRIALS
Pharmaceutical and biotech companies interested in marketing a drug or
biologic in the U. S. must first submit a marketing application to the FDA.46
The Federal Food, Drug, and Cosmetic Act requires all new investigational
drugs to undergo clinical trials on human subjects which demonstrate the
safety and efficacy of these products prior to their approval for marketing. 4 7
Sponsors must submit clinical trial results with their marketing
applications.4 8 The FDA generally bases its approval to market a new drug
(Trovafloxacin/AlatrofloxacinMesylate), U.S. FOOD & DRUG ADMIN., http://www.fda.gov/
Drugs/DrugSafety/PostmarketDrugSafetylnformationforPatientsandProviders/DrugSafetylnf
ormationforHeathcareProfessionals/PublicHealthAdvisories/UCMO53103 (last updated Apr.
30, 2009).
41 Id

42.
43.

See Stephens, supra note 34.
See id

44.

OIG, CHALLENGES, supra note 2, at 2.

45. See Glickman et al., supra note 11, at 817.
46. 21 C.F.R. § 314.50 (2011) (governing New Drug Application (NDA) for drugs); 21
C.F.R. § 601.2 (2011) (governing Biologic Licensing Application (BLA) for a biologic).
47. Food, Drug, and Cosmetic Act of 1938, Pub. L. No. 75-717, 52 Stat. 1040 (1938)
(codified as amended at 21 U.S.C. §§ 301-399a (2004)).
48. 21 C.F.R. § 314.50(d)(5) (2011); 21 C.F.R. § 312.21 (2011) (including information
from all phases of clinical trials. Phase I includes the initial introduction of an
investigational new drug into humans, Phase I studies are typically closely monitored and
may be conducted in patients or normal volunteer subjects. These studies are designed to
determine the metabolism and pharmacologic actions of the drug in humans, the side effects
associated with increasing doses, and, if possible, to gain early evidence on effectiveness.
Phase II includes the controlled clinical studies conducted to evaluate the effectiveness of the
drug for a particular indication or indications in patients with the disease or condition under
study and to determine the common short-term side effects and risks associated with the
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on pivotal Phase III trials. 49 However, the agency considers all clinical
trials when evaluating the safety and efficacy of a drug. 0
An Investigational New Drug Application (IND) provides an exemption
to federal law that prohibits unapproved drugs and biologics from being
Sponsors intending to conduct
introduced into interstate commerce."
clinical trials in the U.S. must submit an IND to the FDA prior to starting
research.5 2 FDA authority to oversee clinical trials begins when a sponsor
submits an IND to the agency.
The FDA reviews the IND for safety to
ensure that subjects are not exposed to unreasonable risk.5 4 Sponsors may
conduct foreign clinical trials under an IND, but because interstate
commerce laws do not extend to foreign countries the IND is unnecessary
for clinical trials conducted outside the U.S. 5
The FDA allows sponsors to submit marketing applications with data
Sponsors may
from foreign clinical trials not conducted under an IND.
also submit results of earlier foreign clinical trials not conducted under an
IND to support a current IND.
If a sponsor wants to submit data from
foreign clinical trials not conducted under an IND, the sponsor must
conduct the trials in accordance with Good Clinical Practice (GCP).58 FDA
regulations require sponsors to submit a description of the actions the
drug. Phase 11studies are typically well controlled, closely monitored, and conducted in a
relatively small number of patients, usually involving no more than several hundred subjects.
Phase III studies are expanded controlled and uncontrolled trials. They are performed after
preliminary evidence suggesting effectiveness of the drug has been obtained, and are
intended to gather the additional information about effectiveness and safety that is needed to
evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for
physician labeling. Phase III studies usually include from several hundred to several
thousand subjects. Phase III trials are the most pivotal trials, evaluating the "overall benefitrisk relationship of the drug and to provide an adequate basis for physician labeling.").
49. OIG, CHALLENGES, supra note 2, at 3.
50. Id.
51. 21 U.S.C.A. § 355(i) (West 2010); 42 U.S.C.A. § 262(a) (West 2010).
52. 21 C.F.R. § 312.20 (2011).
53.

OIG, CHALLENGES, supra note 2, at 3.

54. 21 C.F.R. § 312.20 (2011); 21 C.F.R. § 312.40 (2011); 21 C.F.R. § 312.42 (2011)
(ensuring INDs provide information on the clinical trial protocol, the qualifications of trial
personnel, and assurances that investigators will protect research subjects' welfare)
55.

OIG, CHALLENGES, supra note 2, at 3.

56.
57.

21 C.F.R. § 312.120 (2011); 21 C.F.R. § 314.106 (2011).
21 C.F.R. § 312.23(b) (2011).

58.

21 C.F.R.

§

312.120(a)(i) (2011); see also INTERNATIONAL

CONFERENCE ON

HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS

FOR HUMAN USE, Guideline for Good Clinical Practice, E6(RI),http://www.ich.org/fileadmin
/PublicWeb Site/ICH
Products/Guidelines/Efficacy/E6_R1/Step4/E6_RI Guideline.pdf
(last visited September 13, 2011) (describing that Good Clinical Practices document the
responsibilities and expectations of all participants in the conduct of clinical trials, including
investigators, monitors, sponsors and IRBs. The GCP also covers aspects of monitoring,
reporting and archiving of clinical trials).
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sponsor or applicant took to ensure that the research conformed to GCP.59
The information provided in the description is similar to the information
provided in an ND.o
The FDA also requires certain clinical trials to be registered in the
publicly accessible databank, ClinicalTrials.gov. 61 The Food and Drug
Administration Amendments Act (FDAAA) extended and expanded the
clinical trial registration requirements of the databank to include all
"applicable clinical trials". 62 "Applicable clinical trials" are post-Phase I
studies subject either to §505 of the FDCA, or §351 of the PHSA.6 ' The
FDAAA requires the sponsor of an applicable clinical trial to submit
information for entry into the databank no later than twenty-one days after
the first subject is enrolled. 4 Additionally, the FDAAA requires that the
results of each applicable clinical trial be reported to the NIH for inclusion
into the databank.
Besides an IND, GCP, and databank registry requirements, the FDA may
conduct onsite inspections to ensure clinical investigators, sponsors, and
independent review boards (IRB) comply with FDA regulations.66 FDA
authority to conduct inspections extends to both foreign and domestic
sites.6
Most inspections occur after the FDA receives a marketing
application, but the Agency may choose to conduct an inspection while a
clinical *trial is* ongoing. 68
1I. ADDRESSING LIMITATIONS TO THE OVERSIGHT OF FOREIGN
CLINICAL TRIALS

Despite seemingly extensive regulations governing the conduct of
59. 21 C.F.R. § 312.120(b) (2011).
60. Id; see also 21 C.F.R. § 312.23(a) (2011) (detailing required IND content).
61. Food and Drug Administration Modernization Act, Pub. L. No. 105-115, §113, 111
Stat. 2296 (1997) (amending the FDCA, 21 U.S.C. § 301 et seq., and the Public Health
Service Act (PHSA), 42 U.S.C. § 201 et seq.).
62. Food and Drug Administration Amendments Act, Pub. L. No 110-85, 121 Stat. 823
(2007) (amending sections of the FDCA, 21 U.S.C. § 301 et seq., § 402 of the PHSA, and 42
U.S.C § 282); see also NIH, DRAFT ELABORATION OF DEFINITIONS (2009), at 7, availableat
http://grants.nih.gov/Clinicaltrials fdaaa/ (last visited November 22, 2010) (defining
"applicable clinical trials" to generally include: trials of drugs and biologics known as
"applicable drug clinical trial" and trials of devices known as "applicable device clinical
trial").

63. 42 U.S.C.A. § 282(j)(1)(A)(iii) (West 2011) (§ 505 of the FDCA codified as 21
U.S.C. § 355 and § 351 of the PHSA codified as 21 U.S.C. 262, governing the use of a drug
or biologic prior to marketing and after approval).
64. 42 U.S.C.A. § 282(j)(2)(C)(ii) (2011).
65. Id.; 42 U.S.C.A. § 282(j)(3)(E)(ii) (2011).
66. 21 C.F.R. § 312.58 (2011); § 312.68 (2011).
67.

OIG, CHALLENGES, supra note 2, at 4.

68.

Id.

http://lawecommons.luc.edu/annals/vol21/iss2/8
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clinical trials and the submission of data, some significant issues arise out
of the FDA's current regulatory scheme. These issues limit the FDA's
ability to ensure the protection of human subjects and the integrity of
clinical trial data. One issue is that the Agency is unable to account for all
clinical trial information, because it often receives clinical trial information
in a nonstandard format. 69 Additionally, the FDA is unaware of ongoing
foreign clinical trials which are not conducted under an IND.70 If the FDA
is to effectively ensure the protection of research subjects and the quality of
clinical trial data, the Agency must at least be aware of any and all foreign
clinical trials that a sponsor may use to support a U.S. marketing
application either before or shortly after those trials begin. Still, the FDA
will not only have to know that these trials exist, it will need to compel
production of complete and timely information so that the Agency may
discern any risks associated with the trials.
For sponsors that conduct foreign clinical trials according to GCP, the
FDA recommends that complete raw data sets of all clinical trials be
Despite current guidelines, sponsors sometimes provide
submitted.7 '
incomplete clinical study reports with missing information regarding site
72
Furthermore, sponsors often submit
locations and subject enrollment.
data in nonstandard and inconsistent formats.73 Nonstandard and missing
data significantly complicate the FDA's ability to provide timely review of
marketing applications. 4 A few months after the release of the OIG report
the FDA issued a final rule amending its regulations governing safety
reporting requirements for drugs and biologics subject to an IND." The
revised rule codified "the agency's expectations for timely review,
evaluation, and submission of relevant and useful safety information" and
implemented "internationally harmonized definitions and reporting

standards." 76
The OIG report also recommended that the FDA require standardized
electronic clinical trial data as well as the creation of an internal database to
assist reviewers in effectively reviewing the data.n The FDA could simply
create a rule to compel sponsors to submit standardized raw data. This rule
would enable the FDA to ensure reviewers have all the information needed

69.
70.
71.
72.
73.

74.
75.
76.
77.

Id
Id. at 17-18.
Id. at 18.
Id.
01G, CHALLENGES, supra note 2, at 19.
Id.
75 Fed. Reg. 59, 935 (Sept. 29, 2010).
Id.
OlG, CHALLENGES, supra note 2, at 20.
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to more effectively review the data.78
Sponsors and investigators should welcome requirements for
standardized data. Standardization of data would arguably make it easier for
investigators or sponsors to address FDA reviewers' inquiries regarding a
particular trial by enhancing communication of the parties through the use
of one universally recognized form of communication. The efficiency
associated with data standardization and an internal database could speed up
the time needed to grant marketing approval, saving sponsors time and
money. Consequently, increased standardization may have the effect of
making foreign clinical trials even more desirable to sponsors. Regardless,
even with better standardization requirements, the trend of increasing
utilization of foreign clinical trials, including those not conducted under an
IND, will inevitably continue.79 At very least, by insisting that sponsors
submit complete and standardized data, the FDA could begin to better
evaluate foreign clinical trials and address potential and actual problems
before they rise to the level of Kano.
An internal database of standardized data would also enable the FDA to
more effectively select sites for inspection. According to the FDA, efforts
are currently underway by the Center for Drug Evaluation and Research
(CDER), which serves to promote and protect the health of Americans by
assuring that all prescription and over-the-counter drugs are safe and
effective, to develop standards to be used in conducting a pilot program that
will use the existing data submission framework, to request standardized
data.8 ' The FDA also indicated that a more robust system for uniquely
identifying individual clinical investigators is needed. 8 2 Perhaps requiring
such identifying information when sponsors initially register data could
satisfy this need. In fact, in July 2011, the FDA issued an advanced notice
of proposed rulemaking (ANPRM) "to seek comment on how to better
protect human subjects who are involved in research, while facilitating
valuable research and reducing burden, delay and ambiguity for
researchers."83 The proposed changes to improve the current data collection
system involve; 1) standardized, streamlined set of data elements, 2) a
Federal-wide web-based portal to allow investigators to submit
electronically certain pre- and post-market safety and have the data
78. Id.
79. Id. at 13.
80. Id at 20.
81. Id., at 38. (responding to the Inspector General's comments, FDA officials note that
"if successful, the pilot [program] can be expanded to include all marketing applications with
clinical data submitted to CDER and would enable more effective targeting of limited
inspection resources . .
82. Id.
83. 76 Fed. Reg. 44,512 (July 26, 2011).
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automatically delivered to the appropriate agencies and oversight bodies, 3)
and harmonizing safety reporting guidance across all Federal agencies,
including harmonizing terminology and clarifying scope and timing of such
reports.8 4 Whatever the ultimate method of collection, utilization of an
internal database of robust, complete, and standardized registration and
results data is an important step toward meaningful improvement in the
efficient analysis of submitted data.
Still, any such requirements for standardized data and an internal
database cannot be fully effective if the FDA is unaware of some ongoing
foreign clinical trials. The OIG report indicated that sponsors are
increasingly conducting early-phase foreign clinical trials without INDs
Sponsors submit clinical trial results to support their marketing applications
years after the start of trials.86 Without an [ND, in most cases, FDA is
uninformed of ongoing foreign clinical trials until the trial data is submitted
in support of a U.S. marketing application. 87 To further assess this
situation, the OIG recommended that the FDA monitor trends in foreign
clinical trials not conducted under an [ND." Retrospective analysis of data
could help identify risks associated with these trial sites. As sponsors
submit clinical trial results in conjunction with marketing applications, the
FDA could assess whether subjects were exposed to increased risk and
whether collected data were accurate and reliable. 89 In the event the FDA
identified particular problems, the agency could use its authority to delay
approval or disqualify data altogether.
However, even if reviewers did identify potential problems regarding
adequate subject protection it would generally be too late to prevent the
harm to which human subjects were exposed. Under current requirements
it seems the FDA lacks the authority to concurrently monitor these ongoing
trials.90 Additionally, sponsors are not required to enter data into the
registry mandated by the FDAAA for Phase I foreign clinical trials.9 1 This
lack of oversight can be increasingly dangerous given that Phase I trials
may pose greater risk for subjects because the products being researched
have yet to be tested widely in humans, and represent the first opportunity
for researchers to evaluate safety and side effects on living subjects.92
Surely, the FDA cannot be expected to adequately provide subject
84.
85.
86.
87.
88.
89.
90.
91.
92.

Id.
OG, CHALLENGES, supra note 2, at 17.
Id.
Id. at 17 and 18.
Id. at 20.
Id.
Id.
42 U.S.C. § 282(j)(1)(A)(iii) (2011).
OIG, CHALLENGES, supra note 2, at 17.
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protection when the Agency has no idea where foreign non-IND trials are
taking place. This conundrum presents the questions: how does the FDA
become aware of ongoing foreign clinical trials and how can it effectively
ensure data quality and adequate human subject protection before the trial
results data are submitted to support a marketing application?
In an effort to find a solution to this problem, the OIG recommended that
the FDA encourage sponsors to either voluntarily consult with the FDA
about clinical trial protocols or submit an IND.9 3 An IND provides a level
of FDA oversight before human subjects are enrolled. In the event that
concerns are indentified, the Agency would have the ability to prevent trials
from starting, or require sponsors to adjust study protocol.
After
submission of an IND, the FDA also has the opportunity to conduct realtime inspections.94 Encouragement of INDs submissions or voluntary
consultations might work for some sponsors if they have an incentive to
comply. Cooperating along these lines shows goodwill towards the FDA,
potentially making it easier to resolve issues with the FDA if they arise.
Also, by providing study information voluntarily before studies begin, the
sponsor cuts down on the chances that a marketing application will be held
up, thus minimizing potential delays in bringing the product to market.
The FDA could also provide other incentives to promote INDs.95
However, before incentives are legislated, care should be taken to ensure
that any such incentives will have the desired effect. Merely encouraging
the submission of IND's seems like a rather conciliatory approach to trying
to get a handle on the problems associated with foreign clinical trials.
Despite incentives, some sponsors may still feel it is in their interests to
only adhere to the current regulations. Although earlier assertions noted
that widespread adoption of international standards may contribute to the
increase in foreign clinical trials, sponsors may engage in a "race to the
bottom," instead seeking out certain nations that have lax regulations or are
known to largely ignore shortcuts around GCP standards. Sponsors may
find that avoiding additional scrutiny may prove to be more beneficial than
providing study information before submitting a marketing application to
the FDA.
If the FDA wanted to monitor ongoing foreign clinical trials it should
require sponsors to submit study information before research begins, similar
to the effect of an IND. Such a rule would require registration of pre-trial
data for any sponsor that anticipates marketing a drug in the U.S. using data
from foreign clinical trials not conducted under an IND. However, there

93.
94.
95.

Id. at 21.
Id.
Id.
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would likely be significant pushback by industry against such requirements.
It is also questionable whether the FDA has the authority to require this
data.
NIH guidelines provide some clarification as to whether certain foreign
clinical trials are considered "applicable drug clinical trials," subjecting
them to FDAAA registration and reporting requirements.96 According to
draft regulations, when a clinical investigation includes sites both within
and outside the U.S., all trials included in the investigation are considered
"applicable drug clinical trial[s]." 9 7 A clinical investigation conducted
exclusively outside the U.S. is deemed an "applicable drug clinical trial" if
the product is subsequently manufactured in the U.S. 98_Of course, foreign
clinical trials conducted under an IND are deemed "applicable drug clinical
trial[s]." 99 If all trial sites are outside the U.S., the trials are not conducted
under an IND, and the drug is manufactured outside of the U.S., then the
investigation is not considered an "applicable drug clinical trial." 00
Consequently, these drugs are not subject to either §505 of the FDCA or
§351 of the PHSA.' 0' However, the draft elaboration does not address the
situation wherein foreign clinical trials are not conducted under an IND, the
product is not manufactured in the U.S., but the sponsor subsequently seeks
U.S. marketing approval. 10 2 One could interpret that such a trial becomes
subject to FDA requirements after the sponsor submits the marketing
application with all clinical trial information, triggering the FDAAA's
registration obligations. 0 3 Because the study would only become subject to
the registration requirements after the trial had already been completed, a
sponsor or investigator could not meet the registration requirements within
21 days of the first subject's enrollment.10 4 Unless a sponsor anticipated
that the trial would subsequently be used to support a U.S. marketing
application and voluntarily submitted the information the sponsor could not
comply with the registration timeline.'os
If this interpretation is correct, the FDA would need to clarify this
ambiguity. It has been suggested that the FDA could carve out an
96. See Nat'1 Insts. of Health, Draft, ElaborationofDefinitionsofResponsible Party and
Applicable Clinical Trial, 4-10 (March 9, 2009), http://prsinfo.clinicaltrials.gov/
ElaborationsOnDefinitions.pdf.
97. Id. at 8.
98. Id.
99. Id
100.
d. at 7.
101. Id at 8.
102. Carolyne R. Hathaway et al., The Web of Clinical Trial Registration Obligations:
Have Foreign Clinical Trials Been Caught?, 64 Food & Drug L.J. 261, 269 (2009).
103. Id. at 269-70.
104. Id at 270.
105. Id
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exception to the registration obligation that attaches to a foreign trial not
conducted under an IND and using products not manufactured in the U.S. .
The FDA could require registration of information that is only feasible
when the study becomes an applicable clinical trial, thus eliminating the
timeline requirement. 106 In the alternative, the FDA should require
registration of study information to include these non-IND foreign clinical
trials, thus compelling sponsors to anticipate whether they will use a foreign
trial for subsequent U.S. marketing applications. The creation of such a
rule would expand the FDA's oversight to ongoing non-IND foreign
clinical trials, which do not use products manufactured in the U.S. This
rule would be consistent with the clinical registry's stated purpose of
increased transparency of clinical trials for products marketed in the U.S. 07
The FDA is currently assessing to what extent the ClinicalTrials.gov
database could be used to obtain information on foreign clinical trials not
conducted under an IND. 08 If a rule is not possible then new legislation
would have to provide the FDA with the appropriate authority.
Expanding registration requirements to these non-IND foreign clinical
trials would provide the FDA with more complete and current information
to evaluate ongoing foreign clinical trials. However, paper reviews of data
submissions required under something similar to IND may be considered
fairly passive oversight. The real tool in the FDA's regulatory arsenal is its
ability to conduct site inspections. New registration requirements combined
with requirements for data standardization and a robust data management
system would make monitoring trends and subsequent data analysis more
effective in assessing risks associated with foreign clinical trials.
Consequently, if the Agency utilizes the information to identify high risk
trials, inspections of foreign clinical trial sites would be a more effective
enforcement tool.
Regression analysis indicated that the Agency was sixteen times more
likely to inspect a clinical investigation at a domestic site than a foreign
site.109 The OIG noted that FDA could inspect clinical trials in more
countries, targeting trials in those countries that the agency has not
previously inspected or where GCP standards have recently been
adopted."10 Inspecting more sites would require more resources, yet
resource constraints already limit the number of foreign clinical trial site
In addition, inspections of foreign sites are usually
inspections.'

106.
107.
108.
109.
110.
111.

Id.
Id.
OIG, CHALLENGES, supra note 2, at 39.

Id. at 16.
Id.at21.
Id.
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Conducting
conducted after a clinical trial is already completed.
inspections in this manner is not the most effective strategy to get sponsors
and investigators to comply with regulations, and, by then, it is too late to
However, increasing
correct possible data or ethics problems.l 12
inspections of foreign clinical trials while they are actually ongoing would
prove to be far more effective of an enforcement strategy. Targeting
clinical trials in countries not previously inspected or where GCP standards
are novel could be more effective if the FDA used registration data
submitted to the Agency either before or concurrent to the beginning of a
trial to specifically pursue ongoing high risk clinical trial sites. The Agency
already conducts inspections of domestic early-phase clinical trials on a
targeted basis, thus the FDA could target ongoing early-phase foreign trials
for inspection as well."' By specifically targeting ongoing high-risk
foreign trials, the FDA would maximize its limited resources.
The FDA may not be able to obtain data on these ongoing foreign
clinical trials if an applicable rule is not possible under statute, or if
legislation fails. The FDA may also be reticent to expand its registration
requirements in consideration of the sovereignty of other countries and the
role of foreign regulatory authorities.' 14 In addition, FDA inspections of
foreign clinical trial sites may duplicate efforts of other regulatory bodies,
unduly burdening sponsors and investigators in complying with separate
findings.' 15 If this is the case, the FDA will need to rely on international
cooperation and agreements with foreign regulatory bodies to effectively
monitor ongoing foreign clinical trials.
A. Regulation through the Alien Tort Statute
If the regulatory gaps had been filled and recommendations of the OIG
had been addressed back in 1996, would the harm have been prevented or
minimized for the children participating in the Kano clinical trials? One
would hope that the primary goal of current foreign clinical trial regulation
would be to prevent a tragedy like the one in Nigeria from occurring again.
Although the child victims of Kano did not receive the benefit of adequate
public health protections, they did eventually get some reprieve in federal
court.
The Alien Tort Statute (ATS) has provided a means for foreign nationals
to bring tort actions committed in violation of the law of nations under the
jurisdiction of the federal district courts." 6 In Abdullahi v. Pfizer, Inc., the
112.
113.
114.

115.
116.

Id. at 36.
Id. at 39.
OIG, CHALLENGES, supra note 2, at 39.
Id. at 40.
Alien Tort Statute, 28 U.S.C.A. § 1350 (West 2011).
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Second Circuit held that the child victims of the Trovan debacle and their
guardians had a cause of action under the ATS for a violation of the norm
of customary international law prohibiting the medical experimentation on
human subjects without their consent (i.e. a violation of informed
consent). 117 Subsequently, the Supreme Court refused to hear Pfizer's
petition for certiorari.' 18 Shortly after, Pfizer announced it had settled all
outstanding lawsuits involving accusations that it tested Trovan on the
children in Nigeria without receiving adequate informed consent.1 19 This
regulation through tort seems to provide a viable forum for clinical trial
subjects whose informed consent rights have been violated.
However, this restitution occurs after the fact of injury. An effective
regulatory scheme should prevent these incidents from occurring in the first
place.
In addition, it is unclear whether future victims could bring an action
under the ATS against corporate defendants. In Kiobel v. Royal Dutch
Petroleum Co., the Second Circuit indicated that the ATS does not confer
jurisdiction for a cause of action against corporations. 2 0 The Second
Circuit's Kiobel decision presents a major roadblock to causes of action
which are similar to the one brought by plaintiffs in Abdullahi. According
to the Kiobel ruling, if a plaintiff brings a cause of action for a violation of
informed consent under the ATS against a corporate defendant like Pfizer,
the complaint may be dismissed merely because ATS does not confer
jurisdiction against such defendants. It is likely that the Supreme Court will
soon have to decide on this apparent inconsistency, but until then, holding
pharmaceutical sponsors liable for violations of informed consent will be an
uncertain option for aggrieved clinical trial subjects. While the potential for
tort litigation in a federal district court may act as a deterrent to violative
conduct, a globalized regulatory system focused on preventative public
health monitoring and regulation is a more viable and effective option.
III. TOWARDS A GLOBALIZED REGULATORY SCHEME
The ICH-GCP guidelines provide a good framework for standardization

117. Abduhalli v. Pfizer, Inc., 562 F.3d 163, 187 (2d Cir. 2009) (holding that Nigerian
children and their guardians alleging a violation of the prohibition on nonconsensual medical
experimentation had standing under the Alien Tort Statute).
118. Pfizer, Inc., v. Abdullabi, 562 F.3d 163 (2d Cir. 2009), cert. denied, 130 S.Ct. 3541
(2010).
119. Bill Berkrot, Pfizer settles remainingNigeria, US Trovan suits, REUTERS (February
22, 2011, 6:18 PM),
http://af.reuters.com/article/investingNews/idAFJOE71LOMV20110222.
120. Kiobel v. Royal Dutch Petrol. Co., 621 F.3d 111, 145 (2d Cir. 2010) (holding ATS
confers jurisdiction only over claims against individuals, not corporate entities; thus the
corporate defendant was not subject to liability under the ATS).
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and ethical oversight of clinical trials globally. The FDA and European
Medicines Agency (EMA) are currently collaborating on inspections
through their GCP Initiative, designed to identify areas of harmonization,
share, and effectively utilize resources for joint inspections. 12 1 Continuing
harmonization efforts and joint inspections with EMA are positive steps
toward implementing best practices for conducting inspections, reducing
duplicative inspections, and fostering understanding and collaboration
between international regulatory agencies.122 The Initiative could set the
tone and provide groundwork for other regulatory authorities, especially in
those of developing or emerging countries, for the acceptance and
adherence to harmonized global standards for conducting clinical trials. To
further the goal of harmonization and global adherence to GCP, the FDA
engages in outreach and capacity building throughout the world.123 The
goal of the FDA outreach is not only to ensure that foreign countries
develop an understanding of the clinical trial oversight process and to
incorporate GCP into their regulatory processes, but also to provide training
and expertise to these countries.124
Another example of multinational collaboration is the Pan American
Network for Drug Regulatory Harmonization (PANDRH), which provides a
forum for the FDA to work with all countries in the Americas to focus on
harmonization of drug regulation. 12 5 Additionally, the FDA recently
established permanent international presence in Latin America, Europe, the
Middle East, Africa, India, and China to leverage the activities and
resources of trusted regulatory foreign counterpart regulatory authorities. 126
Hopefully the FDA furthers these efforts to areas of the globe where
regulatory authorities are not as "trusted" and clinical trial oversight is not
yet as developed. FDA should also continue to develop inspectional
agreements, especially with the emerging BRIC and developing countries to
further the goals of ensuring data quality and human subject protection. 127
While harmonization, collaboration, and joint inspections are particularly
important to effective and ethical oversight of clinical trials, the FDA
should still pursue efforts to acquire standardized data from ongoing foreign

121. OIG, CHALLENGES, supra note 2, at 40 (noting that the EMA is an agency of the
European Union, located in London, and is responsible for the scientific evaluation of
medicines developed by pharmaceutical companies for use in the European Union).
122. Id.
123. Id. at 6-7.
124. Id at 7.
125. Id.
126. International Programs: FDA Globalization, U.S. FOOD AND DRUG
ADMINISTRATION,http://www.fda.gov/lnternationaPrograms/FDABeyondOurBorders
ForeignOffices/default.htm (last updated July 21, 2011).
127. BRIC countries include Brazil, Russia, India, and China.

Published by LAW eCommons, 2012

17

Annals of Health Law, Vol. 21 [2012], Iss. 2, Art. 8

510

Annals of Health Law

[Vol. 21

clinical trials that will be used to support U.S. marketing applications.
International data sharing agreements could help solve the problem
concerning the lack of information on ongoing foreign clinical trials. The
FDA could create multilateral data-sharing agreements with other countries,
including data for Phase I trials. Access to an international trial registry
would also help close the data gap. The FDA and other regulatory bodies
could link into clinical trial registries and exchange information.
The World Health Organization (WHO) currently maintains the
International Clinical Trials Registry Platform (ICTRP) as means to access
trial registration data sets provided by international clinical trial registries,
including ClinincalTrial.gov.128 The ICTRP could feasibly serve as a
means for more robust data sharing. The FDA could link into the ICTRP
for complete standardized data when the Agency needs to obtain
information on foreign clinical trials not conducted under an IND. The
FDA would be able to utilize the ICTRP as a public health surveillance tool
for clinical trials. Data monitoring and statistical analysis could be done
through access to the trial registration data sets. When inconsistencies and
unusual patterns in the data are found, WHO registry network member
countries could be alerted to concerns related to the identified clinical
trials. 129 Countries that insist on not bringing their regulatory schemes up to
acceptable international standards and refuse to participate in an
international data sharing agreement could be listed publicly on the WHO
ICTPR website. This sort of "black list" would provide some incentives for
these countries to catch up to acceptable standards. The list may also scare
pharmaceutical companies away from sponsoring trials in these countries.
Sponsors may bring more scrutiny upon themselves from the FDA when
they submit information indicating their trials were conducted in these
pariah countries. Overall, international data sharing and an international
clinical trial registry are pragmatic solutions to the FDA's limitations to
sufficient foreign clinical trial oversight.
The emergence and utilization of foreign clinical trials to support U.S.
marketing applications have presented the FDA with significant issues
regarding its oversight of these clinical trials, specifically its limited
128. The ICTRP is a global initiative that aims to make information about all clinical
trials involving humans publicly available. It aims to improve the comprehensiveness,
completeness and accuracy of registered clinical trial data, to communicate and raise
awareness of the need to register clinical trials, to ensure the accessibility of registered data,
to build capacity for clinical trial registration, to encourage the utilization of registered data,
and to ensure the sustainability of the ICTRP. See Welcome to the WHO ICTRP, WORLD
HEALTH ORGANIZATION, http://www.who.int/ictrp/en/ (last visited, Jan. 11, 2012).
129. The WHO Registry Network provides prospective trial registries with a forum to
exchange information and work together to establish best practice for clinical trial
registration. See The WHO Registry Network, WORLD HEALTH ORGANIZATION,
http://www.who.intlictrp/network/en/_ last visited, Jan 11,2012).
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awareness of ongoing foreign trials, the ability to obtain complete and
quality data, and to ensure the ethical treatment of human research subjects.
In order to protect the public health by assuring the safety and efficacy of
drugs and biologics, the FDA must progressively adapt its regulation of
foreign clinical trials to keep pace with globalization. Ultimately, if FDA
oversight of foreign clinical trials is to improve the agency must first
address limitations of the data that is submitted from sponsors and clinical
investigators. The FDA should require more robust and standardized
electronic clinical trial data and continue to build upon its clinical trials
registry and internal database. With more complete data, the FDA will be
able to perform analyses and monitor trends to determine where problems
exist and more effectively target inspections. To effectively monitor
foreign clinical trials, the FDA will have to become aware of any and all
foreign clinical trials that sponsors will utilize for U.S. marketing
applications before the trials begin or while they are still ongoing. Thus, to
tackle concerns with the conduct of foreign clinical trials the Agency will
have to expand its regulatory oversight over these trials. If the FDA cannot
do this through its administrative authority or through new legislation, it
will have to look increasingly towards the international community for
cooperation and further harmonization.
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